|
Arthritis News |
|
Arthritis News From Medical News Today
|
Latest Arthritis News From Medical News Today.
|
-
Actemra Inhibits Joint Damage And Improves Physical Function Of Patients With Rheumatoid Arthritis
Roche announced that Actemra (tocilizumab) can significantly inhibit structural damage to joints in patients with rheumatoid arthritis (RA), a critical measure of effectiveness of an RA treatment. Actemra also improved the patients' physical function after one year of therapy, leading to a better quality of life.
-
New CDC Study Finds Arthritis Can Be A Barrier For Adults Seeking To Manage Diabetes Through Physical Activity
More than half of adults with diagnosed diabetes also have arthritis, a painful condition that can be a barrier to physical activity-an important health strategy for managing diabetes, according to a study released by the Centers for Disease Control and Prevention in todayâ?²s Morbidity and Mortality Weekly Report.Nationwide, 46.4 million adults have arthritis and 20.6 million adults have diabetes, with nearly 7 in 10 having had diabetes diagnosed by a health professional.
-
Arthritis Unnecessarily Stops Many US Diabetics Taking Needed Exercise
About half of US adults with diabetes also have arthritis, which appears to be a barrier, in addition to lack of time and being too busy with other things, because they are not sure what exercise is appropriate and they are concerned about aggravating joint pain and causing further damage. The researchers suggest health care providers pay special attention to arthritis-related barriers among diabetics who are not physically active.
-
Risk Of Knee Osteoarthritis Progression May Be Reduced By Use Of A Cane
A common, incurable joint disease, osteoarthritis (OA) is the leading cause of disability in elderly people. While nearly any joint can be affected, OA most often strikes the knee, particularly the inner aspect of the tibiofemoral joint. One source of stress on this vulnerable joint compartment is the knee adduction moment, an indication of weight placement while walking.
-
Increased Risks For Infection And Dislocation Faced By Obese Patients Following Revision Hip Replacement Surgery
Along with age and injuries, obesity is a leading risk factor for osteoarthritis (OA), a painful and disabling joint disease. While excessive weight can aggravate the toll on almost any joint, obesity has been associated with a higher prevalence of hip OA and an increase in total hip arthroplasty (THA). Whether obese hip OA patients are more prone to postsurgical complications, however, remains open to debate and investigation, since the results of existing studies conflict.
-
Medication For Juvenile Rheumatoid Arthritis Confirmed Effective By Study
Juvenile rheumatoid arthritis (JRA) is a chronic autoimmune disease that strikes children between the ages of newborn to 16 years. All children with JRA have joint pain, stiffness, and swelling and some also have fever and skin rashes. JRA can impede growth, damage joints, and lead to disability in adulthood.
-
Molecular Response Of Cartilage To Injury Identified By Study
It's an unfortunate fact backed by studies of former professional football and soccer players: injury to joint cartilage escalates the risk of developing of osteoarthritis (OA). However, why this occurs - the details of how joint cartilage cells respond to acute trauma and how this response leads to progressive cartilage degradation - remains open to investigation.
-
Rheumatoid Arthritis: Fully-automated Anti-CCP Assay Launched By Roche Diagnostics
Roche Diagnostics announced the launch of a fully-automated immunoassay for the determination of autoantibodies to cyclic citrullinated peptides (Anti-CCP). The assay has been CE approved for use on the Elecsys / cobas e electrochemiluminescence immunoassay systems. The results of the Anti-CCP assay are intended to be used as an aid in the diagnosis of Rheumatoid Arthritis (in combination with other clinical and laboratory findings).
-
Trubion Announces Initiation Of Phase 2b Study Of TRU 015 For The Treatment Of Rheumatoid Arthritis
Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) announced that its partner, Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), has commenced patient dosing in the next Phase 2b clinical trial of TRU-015 in patients with rheumatoid arthritis (RA). In collaboration with Trubion, Wyeth Pharmaceuticals is developing TRU-015, SBI-087 and other CD20-directed products.
-
A Bit Of Reassurance On Lyme Disease
Tick bites generate fears of Lyme disease in every parent, but this study of 99 children finds that one of Lyme's complications -- arthritis -- has a good prognosis. Researchers led by Robert Sundel, MD, a rheumatologist at Children's, found that 77 percent of children were cured with less than 3 months of antibiotic treatment. The remainder were also ultimately relieved of their arthritis, though additional treatment (usually one month of intravenous antibiotics) was required.
|
|
News & Information 
